Launches Clinical Quality Improvement Study for GORE@ DUALMESH@ Biomaterial in Laparoscopic Repair for Ventral Hernia Patients
FLAGSTAFF, Ariz. & WASHINGTON--(BUSINESS WIRE)--Jun 14, 2012-- W. L.
Gore & Associates (Gore) continues its commitment to improving patient outcomes in hernia patients, with the launch of a clinical quality improvement (CQI) study for GORE(R) DUALMESH(R) Biomaterial in laparoscopic repair for ventral hernia patients. Announced at the Abdominal Wall Reconstruction Conference 2012, taking place in Washington D.C., the CQI study will focus on ways to improve the patient and physician experiences in enhancing patient outcomes.
Gore is working with Surgical Momentum to implement the study. The methodology of continuous quality improvement will be used to support, analyze and advance patient care. The goal of the CQI study is to emphasize better communication and coordination between all stakeholders, to improve clinical results and ultimately the lives of hernia patients. The teams are working to define the clinical processes, size of the patient population and outcomes to be measured for the study. The initial phase is expected to last at least one year.
Introduced in 1993, GORE DUALMESH Biomaterial is a soft, conformable, ePTFE material that offers a unique, two-surface design intended for such applications. Improved in 1999 by developing the textured CORDUROY surface, the biomaterial features two functionally distinct surfaces: the CORDUROY surface to encourage host tissue incorporation and the smooth surface to minimize tissue attachment to the material.
The Gore Biomaterial permits the permanent repair of the abdominal wall, has ingrowth characteristics that mimic normal tissue healing, easily assumes the conformity of the abdominal wall musculature anatomy and can be cut easily without fraying. The clinical reputation of GORE DUALMESH Biomaterial for the repair and reconstruction of ventral hernias is well known, exceeding 150 peer-reviewed scientific articles published since 1996 and more than 19 years of clinical history.
"The launch of a clinical quality improvement study for GORE DUALMESH Biomaterial is an example of Gore's commitment to enhancing the quality of patient care, which is at the core of everything we do," said Ron Anderson, Business Leader with the General Medical Products Business. "Gore has served a variety of markets for more than 50 years and remains dedicated to providing its customers with high-value products that drive results." "We are very pleased to be working with Gore Medical on this important project," said Dr. Bruce Ramshaw, Chief Medical Officer and founder at Surgical Momentum. "Gore is a leader in medical device innovation and the company's commitment to improving patient care, coupled with its corporate culture, is an inspiration." ABOUT SURGICAL MOMENTUM Surgical Momentum was formed to apply complex science principles to improve health care. It utilizes innovative models, such as patient-centered care and clinical quality improvement to deliver better patient outcomes, better products and lower overall costs of care.
ABOUT W. L. GORE & ASSOCIATES The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide.
The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 15th consecutive year. For more information, visit www.goremedical.com.
Products listed may not be available in all markets. GORE(R), CORDUROY, DUALMESH(R), and design are trademarks of W. L. Gore & Associates. 5/8 2012 W. L Gore & Associates, Inc.
CONTACT: Chempetitive Group for W. L. Gore & Associates Kena Hudson or Rachel Lear +1 510-908-0966 GoreMedical@Chempetitive.com KEYWORD: UNITED STATES NORTH AMERICA ARIZONA DISTRICT OF COLUMBIA INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY CLINICAL TRIALS HOSPITALS MEDICAL DEVICES SOURCE: W. L. Gore & Associates Copyright Business Wire 2012 PUB: 06/14/2012 08:00 AM/DISC: 06/14/2012 08:00 AM http://www.businesswire.com/news/home/20120614005059/